Transcatheter versus surgical aortic valve replacement: what does the latest evidence tell us?

The ongoing uncertainty about the place of transcatheter aortic valve replacement (TAVR) was addressed by emerging evidence presented in part at the American College of Cardiology meeting (16–18 March 2019 New Orleans) and in the New England Journal of Medicine. Edward Scientific’s PARTNER 3 trial [1] and Medtronic’s Evolut Low Risk Trial (LRT) [2] were both simultaneously presented and published in the New England Journal of Medicine.